Answers are grounded in this paper and cite their sources.
Meta-analysis demonstrates high diagnostic accuracy for artificial intelligence in dermatological patients, highlighting challenges in cost-effectiveness and equity across skin types.
Background: Artificial intelligence (AI) has emerged as a transformative technology across dermatological practice, from automated lesion classification to whole-slide pathology analysis. Despite rapid growth in primary studies, a comprehensive synthesis of diagnostic performance, application breadth, and real-world implementation remains lacking. Methods: We conducted a PRISMA systematic review and meta-analysis of studies published from January 2000 to March 2025. We searched the PubMed, Cochrane, and ScienceDirect databases for studies reporting AI diagnostic performance in dermatology. Results: Of 30 included studies (28 valid after exclusion of two retracted publications), 60% focused on melanoma and related lesions. AI diagnostic performance improved markedly over five identified temporal eras (2003–2025), with a pooled AUROC of 0.92 (95% CI 0.87–0.96), Reitsma sensitivity of 0.88 (0.82–0.93), and Reitsma specificity of 0.85 (0.75–0.91). AI matched or surpassed specialist dermatologists in 71% of direct comparisons. Three randomized controlled trials (RCTs) were identified, with heterogeneous findings across different clinical applications: AI assistance significantly improved non-expert diagnostic accuracy in one trial (53.9% vs. 43.8%; p = 0.019), significantly reduced acne severity via personalized treatment recommendations in a second, and showed non-inferior diagnostic performance, but was not cost-effective in the third. The sole cost-effectiveness analysis found AI-assisted surveillance not cost-effective over a 2-year horizon. Conclusions: AI achieves dermatologist-level diagnostic accuracy in controlled settings; however, real-world evidence, algorithmic equity across skin phototypes, and health economic viability remain critical unresolved challenges. Prospective validation, mandatory demographic subgroup reporting, and cost-effectiveness modeling are essential prerequisites for safe and equitable clinical implementation.
No takes yet. Share an insight, caveat, or question.
Ivanović et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: